## Natural History of Ascending Aortic Aneurysms (40-50 mm): Impact of Bicuspid Aortic Valves

Tarek Malas<sup>1</sup>, Eric Dumont<sup>1</sup>, Siamak Mohammadi<sup>1</sup>, Pierre Voisine<sup>2</sup>, and François Dagenais<sup>3</sup>

<sup>1</sup>Quebec Heart and Lung Institute <sup>2</sup>Affiliation not available <sup>3</sup>Institut universitaire de cardiologie et de pneumologie de Quebec


November 11, 2020


## Abstract


Background: Growth of ascending aortic aneurysms in bicuspid aortic valve (BAV) patients is controversial. Methods: To evaluate the natural history of medically treated ascending aortic aneurysms and the impact of BAV, 572 patients (104 pts BAV; 468 pts with tricuspid aortic valve(TAV) with 40-50mm ascending aortic aneurysms were followed prospectively in a dedicated thoracic aortic clinic. Results: Patients with BAV were younger (BAV:  $56.5\pm10.6$  vs. TAV:  $66.9\pm9.9$ ; p<0.0001) and less high blood pressure (BAV:54.4% vs. TAV:69.2%; p=0.01). Maximal ascending aortic diameter was significantly larger in BAV vs. TAV patients ( $46.5\pm2.3$  vs.  $45.2\pm3.0$ ; p<0.0001). Mean follow-up was  $3.9\pm2.5$  years. Significantly more patients were operated during follow-up for the ascending aorta or the aortic valve in the BAV group (BAV:32.7% vs. TAV:7.3%; p<0.0001). Only one patient with TAV was operated emergently for an acute aortic syndrome. Operative mortality was 0% and overall mortality was 10.3%. Five- and ten-year freedom from ascending aortic aneurysm progression >2 mm was comparable for both groups BAV vs. TAV (96.7% vs. 96.6%) and (91.2% vs. 90.8%) years (p=0.94). Conclusions: Medically treated 40-50mm ascending aortic aneurysm show slow growth rate comparable for BAV and TAV patients. Freedom from acute aortic-related events and survival are very high in both BAV and TAV patients.

## Hosted file

JCS Final Submission.pdf available at https://authorea.com/users/374749/articles/492198natural-history-of-ascending-aortic-aneurysms-40-50-mm-impact-of-bicuspid-aortic-valves







fel	
Q.	
þe	
1ay	
B	
ata	
Ξ.	
red	
iew	
revi	
-13	
be	
en	
þe	
not	
as 1	
l h	
and	
nt	
preprint	
lel	
a L	
This	
7	
039/	
2023	
446	
7.7	
4	
0207	
605	
au.10	
~	
Ħ	
0.2254	
10.	
.org/10	
oi.or	
qo	
https:	
ht	
ission	
0erm	
it pe	
0	
hout pe	
without pe	
se without pe	
without pe	
No reuse without pe	
d. No reuse without pe	
erved. No reuse without pe	
d. No reuse without pe	
eserved. No reuse without pe	
ghts reserved. No reuse without pe	
rights reserved. No reuse without pe	
ghts reserved. No reuse without pe	
rights reserved. No reuse without pe	
. All rights reserved. No reuse without pe	
/funder. All rights reserved. No reuse without pe	
der. All rights reserved. No reuse without pe	
/funder. All rights reserved. No reuse without pe	
e author/funder. All rights reserved. No reuse without pe	
the author/funder. All rights reserved. No reuse without pe	
e author/funder. All rights reserved. No reuse without pe	
is the author/funder. All rights reserved. No reuse without pe	
is the author/funder. All rights reserved. No reuse without pe	
is the author/funder. All rights reserved. No reuse without pe	
right holder is the author/funder. All rights reserved. No reuse without pe	
ght holder is the author/funder. All rights reserved. No reuse without pe	
copyright holder is the author/funder. All rights reserved. No reuse without pe	
right holder is the author/funder. All rights reserved. No reuse without pe	
The copyright holder is the author/funder. All rights reserved. No reuse without pe	
) — The copyright holder is the author/funder. All rights reserved. No reuse without pe	
020 - The copyright holder is the author/funder. All rights reserved. No reuse without pe	
> 2020 - The copyright holder is the author/funder. All rights reserved. No reuse without pe	
2020- The copyright holder is the author/funder. All rights reserved. No reuse without pe	
> 2020 - The copyright holder is the author/funder. All rights reserved. No reuse without pe	
ea 11 Nov $2020 - $ The copyright holder is the author/funder. All rights reserved. No reuse without pe	
rea 11 Nov $2020 - $ The copyright holder is the author/funder. All rights reserved. No reuse without pe	
ea 11 Nov $2020 - $ The copyright holder is the author/funder. All rights reserved. No reuse without pe	
Authorea 11 Nov $2020 - $ The copyright holder is the author/funder. All rights reserved. No reuse without pe	
on Authorea 11 Nov $2020 -$ The copyright holder is the author/funder. All rights reserved. No reuse without pe	
Authorea 11 Nov $2020 - $ The copyright holder is the author/funder. All rights reserved. No reuse without pe	